

CURRICULUM VITAE

MICHAEL GHERMEZI

POSITIONS:

08/2021-2024	Staff Physician, Cedars Sinai Procedure Center
08/2021-2026	Attending Physician, Cedars Sinai Emergency Department
8/2024-8/2025	Pain Medicine Fellow, Cedars Sinai Medical Center
2020-Present	Emergency Medicine Physician, Kaiser Permanente Los Angeles and West Los Angeles Medical Centers
8/2026-Present	Pain Medicine Physician, California Back and Pain Specialists

PROFESSIONAL CONTACT INFORMATION:

<http://michaelghermezimd.com/>

EDUCATION:

06/2012	B.A. Molecular, Cell and Developmental Biology; UCSB
06/2013	M.S. Clinical Nutrition; Columbia University College of Physicians and Surgeons
05/2017	M.D. Sackler School of Medicine
05/2021	Residency- Emergency Medicine; Harbor-UCLA Medical Center
8/2025	Fellowship- Pain Medicine; Cedars Sinai Medical Center

LICENSURE:

DEA Active
California Medical License Active

BOARD CERTIFICATION:

07/2023-12/2028 American Board of Emergency Medicine

PROFESSIONAL ACTIVITIES:

01/2023-2025	Cedars Sinai Procedure Center MD/RN Alignment Committee
2017-2021	American College of Emergency Physicians
2017-2021	Society for Academic Emergency Medicine
2017-2021	American Medical Association
2017-2021	Emergency Medicine Residents Association

HONORS AND SPECIAL AWARDS:

2008-2012	Magna Cum Laude, UCSB
2008-2012	Distinction in Major with Honors, UCSB
2008-2012	Academic Excellence Award, UCSB
2015-2016	Internal Medicine Outstanding Student Award, Sackler School of Medicine
2015-2017	Clinical Academic Excellence Award, Sackler School of Medicine

RESEARCH AWARDS:

12/2014	Honorable Mention:Annual Sackler Research Symposium, Sackler SOM
03/2015	Abstract Achievement Award, American Society of Hematology
07/2023	Diversity, Equity and Inclusion Ambassador Award, Cedars-Sinai Medical Center
07/2023	Hakimi Award, Cedars-Sinai Medical Center Department of Anesthesia

TEACHING ACTIVITIES:

Clinical Teaching:

05/2017-05/2021	Harbor-UCLA Medical Center, Resident and Medical Student Mentor
08/2021-2026	Cedars-Sinai Emergency Department, Attending Physician and Educator
08/2024-08/2025	Cedars Sinai Pain Medicine Department, Dept. of Anesthesia, Fellow

Non-Clinical Teaching:

05/2017-6/2022	UCLA David Geffen School of Medicine, EM 220 Procedures Course
----------------	--

BIBLIOGRAPHY/PUBLICATIONS:

Research Papers – Peer-Reviewed (Published):

1. Harutyunyan NM, Vardanyan S, **Ghermezi M**, Gottlieb J, Berenson A, Andreu-Vieyra C, Udd K, and Berenson JR. Levels of Uninvolved Immunoglobulins Predict Clinical Status and Progression Free Survival for Multiple Myeloma Patients. British Journal of Haematology. March 2016. PMID: 27017948
2. Schwartz LA, Rozenbaum Z, Ghantous E, Kramarz J, Biner S, **Ghermezi M**, Shimiaie J, Finkelstein A, Banai S, Aviram G, Ingbir M, Keren G, and Topilsky Y. Impact of Right Ventricular Dysfunction and Tricuspid Regurgitation on Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. J Am Soc Echocardiogr. January 2017. PMID: 27742242
3. Kramer J, Biner S, **Ghermezi M**, Pressman G, Shmueli H, Shimiaie J, Finkelstein A, Banai S, Steinvil A, Buffle E, Aviram G, Ingbir M, Nesher N, Keren G, and Topilsky Y. Impact of Left Ventricular Filling Diameters on Outcome of Patients Undergoing Trans-catheter Aortic Valve Replacement . European Heart Journal Cardiovascular Imaging. March 2017. PMID: 27166025
4. **Ghermezi M**, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, Spektor TM, Andreu-Vieyra C, Petraki S, Sanchez E, Udd K, Wang S, Swift R, Chen H, and Berenson

- JR. Serum B-Cell Maturation Antigen: A Novel Biomarker to both Monitor and Predict Outcomes in Multiple Myeloma Patients. *Haematologica*. April 2017. PMID: 28034989
5. Gross Z, Rahbari A, Wirtschafter E, Spektor TM, Udd K, Bujarski S, **Ghermezi M**, Nosrati J, Eades B, Cecchi, G, Maluso T, Swift R, and Berenson JR. Elotuzumab and Dexamethasone for Relapsed or Refractory Multiple Myeloma Patients: A Retrospective Study. *European Journal of Haematology*. March 2018. PMID: 29524348
 6. Rozenbaum Z, Ben Gal Y, Sadeh B, Aviram G, Havakuk O, Shimiaie J, **Ghermezi M**, Laufer-Perl M, Shacham Y, Keren G, Topilsky Y. Combined Echocardiographic and Cardiopulmonary Exercise to assess Determinants of Exercise Limitation in Chronic Obstructive Pulmonary Disease. *Journal of the American Society of Echocardiography*. September 2020.
 7. Rozenbaum Z, Granot Y, Sadeh B, Havakuk O, Arnold J, Shimiaie J, **Ghermezi M**, Barak O, Ben Gal Y, Shacham Y, Keren G, Topilsky Y, and Laufer Perl M. Sex Differences in Heart Failure Patients Assessed by Combined Echocardiographic and Cardiopulmonary Exercise Testing. *Frontiers of Cardiovascular Medicine*. February 2023.

Chapters:

1. Chang C, **Ghermezi M**, Robinson N. Chapter 22: Breech Deliveries. *Manual of Obstetric Emergencies*. June 2020.
2. **Ghermezi M**, Tanen D. Chapter 117: Common Pediatric Ingestions. *Pediatric Emergency Medicine Fundamentals*. January 2021.
3. **Ghermezi M**, Tanen D. Chapter 119: Methemoglobinemia. *Pediatric Emergency Medicine Fundamentals*. January 2021.
4. **Ghermezi M**, Liu T. Chapter 154: Analgesia and Procedural Sedation. *Emergency Medicine Board Review*. June 2021.

Abstracts:

1. Berenson A, Vardanyan S, **Ghermezi M**, Harutyunyan NM, Gottlieb J, Halleluyan R, Andreu-Vieyra C, Swift RA, and Berenson JR. Lack of Significance of ISS Staging and Depth of Response in Predicting Overall Survival of Multiple Myeloma Patients. *Blood* 124(21):5771. December 2014.
2. Harutyunyan NM, Vardanyan S, **Ghermezi M**, Gottlieb J, Berenson A, Andreu-Vieyra C, Tang G, Sanchez E, Li M, Wang C, Ben-Zvi J, Garzio G, Chen H, Finaly J, and Berenson JR. Levels of Uninvolved Immunoglobulin Predict Clinical Status and Progression-Free Survival for Multiple Myeloma Patients. *Blood* 124(21):2125. December 2014.
3. Sanchez E, Gillespie A, Harutyunyan NM, Tang G, Gottlieb J, Vardanyan S, Li M, Andreu-Vieyra C, **Ghermezi M**, Wang C, Ben-Zvi J, Garzio G, Finlay J, Bonavida B, Chen H, and Berenson JR. Circulating BCMA Binding to Its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma Patients. *Blood* 124(21):4713. December 2014.
4. **Ghermezi M**, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, Andreu-Vieyra C, Sanchez E, Swift RA, and Berenson JR. Serum B-Cell Maturation Antigen Is a Novel

Prognostic Indicator for Multiple Myeloma Patients and Correlates with Clinical Status and Survival. *Blood* 124(21):3405. December 2014.

5. Harutyunyan N, Vardanyan S, **Ghermezi M**, Gottlieb J, Berenson A, Andreu-Vieyra C, Tang G, Sanchez E, Li M, Wang C, Ben-Zvi J, Garzio G, Chen H, Finlay J, and Berenson JR. Levels of Uninvolved and Involved Immunoglobulin Predict Clinical Status and Progression Free Survival For Multiple Myeloma Patients. *Hematology Reports (7th International Symposium: Clinical Applications of Free Light Chain and Heavy/Light Chain Analysis)* 7 (s1) p25. April 2015. ISSN: 2038-8322
6. Sanchez E, Gillespie A, Harutyunyan N, Tang G, Gottlieb J, Vardanyan S, Li M, Andreu-Vieyra C, **Ghermezi M**, Wang CS, Ben-Zvi J, Garzio G, Bonavida B, Chen H, and Berenson JR. Soluble BCMA Binds BAFF Resulting in Immune Deficiency in Multiple Myeloma Patients. *Hematology Reports (7th International Symposium: Clinical Applications of Free Light Chain and Heavy/Light Chain analysis)* 7(s1) p62. April 2015. ISSN: 2038-8322
7. Berenson J, Sanchez E, Gillespie A, Harutyunyan N, Tang G, Gottlieb J, Vardanyan S, Li M, Andreu-Vieyra C, **Ghermezi M**, and Wang C. Circulating BCMA Binding to its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma. *Haematologica (20th Congress of the European Hematology Association Meeting)* 100:515. June 2015.
8. Berenson JR, Harutyunyan N, Vardanyan S, **Ghermezi M**, Gottlieb J, Berenson A, Andreu-Vieyra C, Li M, Wang C, Tang G, Sanchez E, Ben-Zvi J, Garzio G, and Chen H. Levels of Uninvolved Immunoglobulin Predict Clinical Status and Progression Free Survival for Multiple Myeloma Patients. *Haematologica (20th Congress of the European Hematology Association Meeting)* 100:740. June 2015.
9. Berenson JR, **Ghermezi M**, Vardanyan S, Harutyunyan N, Spitzer M, Gottlieb J, Berenson A, Andreu-Vieyra C, Li M, Wang C, Sanchez E, Swift RA, and Chen H. Serum B-Cell Maturation Antigen is a Novel Prognostic Indicator for Multiple Myeloma Patients and Correlates with Clinical Status and Survival. *Haematologica (20th Congress of the European Hematology Association Meeting)* 100:93-94. June 2015.
10. Vardanyan S, **Ghermezi M**, Harutyunyan N, Gottlieb J, Berenson A, Andreu-Vieyra C, Sanchez E, Swift R, Chen H, and Berenson JR. Serum B-Cell Maturation Antigen Is A Novel Prognostic Indicator for Multiple Myeloma Patients and Correlates with Clinical Status and Survival. *Clinical Chemistry (American Association for Clinical Chemistry Annual Meeting)* pS126 – Abstract A-355. October 2015.
11. Sanchez E, Gillespie A, Harutyunyan NM, Tag G, Gottlieb J, Vardanyan S, Li M, Andreu-Vieyra C, **Ghermezi M**, Wang CS, Ben-Zvi J, Garzio G, Chen H, and Berenson JR. Circulating BCMA Binding to its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma Patients. *Clinical Chemistry (American Association for Clinical Chemistry Annual Meeting)* pS79 – Abstract A-222. October 2015.
12. **Ghermezi M**, Vardanyan S, Harutyunyan N, David M, Berenson A, and Berenson JR. Serum BCMA: A Novel Prognostic Indicator in Patients with Multiple Myeloma. *Cancer Microenvironment (7th International Conference on Tumor Microenvironment: Progression, Therapy and Prevention)* 8:46. October 2015.
13. Cheng P, Manuk-Hakobyan H, **Ghermezi M**, Van Goringen N, Danovitch I, Margram Y and Vijjeswarapu A. Improving Outpatient Chronic Pain Management and Resident

Education by Developing Collaborative Educational Resources between Internal
Medicine Physicians and Chronic Pain Specialists. Cedars-Sinai Medical Center, Harvey
Morse Auditorium. June 2023